The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin.

Manuele FurnariAlessandra De AlessandriFederico CrestaMaria HauptMarta BassiAngela CalviRiccardo HauptGiorgia BodiniIftikhar AhmedFrancesca BagnascoEdoardo Giovanni GianniniRosaria Casciaro

Published in: Journal of gastroenterology (2018)

CF patients show a high prevalence of SIBO, related to a poorer nutritional status. Rifaximin therapy is well tolerated and the results are promising in terms of efficacy in eradicating small intestinal bacterial overgrowth in CF.

Keyphrases

cystic fibrosis
clinical trial
end stage renal disease
pseudomonas aeruginosa
newly diagnosed
ejection fraction
chronic kidney disease
lung function
prognostic factors
irritable bowel syndrome
study protocol
patient reported outcomes
bone marrow
double blind
replacement therapy
cell therapy